ASTRAZENECA PLC ADR

NASDAQ: AZN (Astrazeneca PLC)

Kemas kini terakhir: 05 Apr, 5:49AM

68.46

-5.46 (-7.39%)

  • 1H -7.39%
  • 5H -7.22%
  • 1B -11.78%
  • 6B -12.34%
  • Tahun Ke Tarikh 3.92%
  • 1T -0.39%
  • 5T 40.63%
Penutupan Terdahulu 73.92
Buka 71.73
Jumlah Dagangan 7,865,852
Purata Dagangan (3B) 5,661,611
Modal Pasaran 230,366,527,488
Harga / Pendapatan (P/E TTM) 30.43
Harga / Pendapatan (P/E Ke hadapan) 16.61
Harga / Jualan (P/S) 4.25
Harga / Buku (P/B) 6.19
Julat 52 Minggu
62.75 (-8%) — 87.68 (28%)
Tarikh Pendapatan 29 Apr 2025
Hasil Dividen (DY TTM) 2.26%
Margin Keuntungan 13.01%
Margin Operasi (TTM) 22.72%
EPS Cair (TTM) 2.25
Pertumbuhan Hasil Suku Tahunan (YOY) 23.80%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 56.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 74.53%
Nisbah Semasa (MRQ) 0.930
Aliran Tunai Operasi (OCF TTM) 11.86 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 8.46 B
Pulangan Atas Aset (ROA TTM) 7.88%
Pulangan Atas Ekuiti (ROE TTM) 17.59%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Bercampur Menaik
Drug Manufacturers - General (Global) Bercampur Menaik
Stok Astrazeneca PLC Bercampur Menaik

AISkor Stockmoo

1.3
Konsensus Penganalisis NA
Aktiviti Orang Dalam NA
Volatiliti Harga 4.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata 1.33

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
AZN 230 B 2.26% 30.43 6.19
SNY 149 B 6.88% 25.00 1.48
AMGN 154 B 3.19% 37.88 26.14
GILD 127 B 3.03% 268.87 7.22
GRFS 6 B - 26.84 0.710
BIIB 21 B - 12.64 1.01

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Growth
% Dimiliki oleh Institusi 17.52%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
31 Mar 2025 Pengumuman IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
31 Mar 2025 Pengumuman ​​AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
26 Mar 2025 Pengumuman Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
25 Mar 2025 Pengumuman New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings
24 Mar 2025 CNBC Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
17 Mar 2025 Pengumuman IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals
17 Mar 2025 Pengumuman EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
14 Mar 2025 Pengumuman AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
07 Mar 2025 Pengumuman IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers
01 Mar 2025 Pengumuman Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
26 Feb 2025 Pengumuman Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
14 Feb 2025 Pengumuman IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
06 Feb 2025 Pengumuman AstraZeneca’s Full Year and Q4 2024 results
27 Jan 2025 Pengumuman ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
17 Jan 2025 Pengumuman CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
17 Jan 2025 Pengumuman DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
Papar semua
Hasil Dividen (DY TTM) 2.26%
Purata Hasil Dividen 5T 2.35%
Nisbah Pembayaran 66.00%
Jangkaan Pembayaran Dividen Seterusnya Sep 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
21 Feb 2025 06 Feb 2025 24 Mar 2025 1.05 Tunai
09 Aug 2024 25 Jul 2024 09 Sep 2024 0.5 Tunai
22 Feb 2024 08 Feb 2024 25 Mar 2024 0.985 Tunai
10 Aug 2023 28 Jul 2023 11 Sep 2023 0.465 Tunai
23 Feb 2023 09 Feb 2023 27 Mar 2023 0.985 Tunai
11 Aug 2022 29 Jul 2022 12 Sep 2022 0.465 Tunai
24 Feb 2022 10 Feb 2022 28 Mar 2022 0.985 Tunai
12 Aug 2021 29 Jul 2021 13 Sep 2021 0.45 Tunai
25 Feb 2021 11 Feb 2021 29 Mar 2021 0.95 Tunai
13 Aug 2020 30 Jul 2020 14 Sep 2020 0.45 Tunai
27 Feb 2020 14 Feb 2020 30 Mar 2020 0.95 Tunai
08 Aug 2019 29 Jul 2019 09 Sep 2019 0.45 Tunai
28 Feb 2019 14 Feb 2019 27 Mar 2019 0.95 Tunai
09 Aug 2018 26 Jul 2018 10 Sep 2018 0.45 Tunai
15 Feb 2018 02 Feb 2018 19 Mar 2018 0.95 Tunai
09 Aug 2017 28 Jul 2017 11 Sep 2017 0.45 Tunai
15 Feb 2017 02 Feb 2017 20 Mar 2017 0.95 Tunai
10 Aug 2016 28 Jul 2016 12 Sep 2016 0.45 Tunai
17 Feb 2016 05 Feb 2016 21 Mar 2016 0.95 Tunai
12 Aug 2015 30 Jul 2015 14 Sep 2015 0.45 Tunai
18 Feb 2015 09 Feb 2015 23 Mar 2015 1.9 Tunai
13 Aug 2014 31 Jul 2014 15 Sep 2014 0.9 Tunai
19 Feb 2014 07 Feb 2014 24 Mar 2014 1.9 Tunai
14 Aug 2013 01 Aug 2013 16 Sep 2013 0.9 Tunai
13 Feb 2013 31 Jan 2013 18 Mar 2013 1.9 Tunai
08 Aug 2012 26 Jul 2012 10 Sep 2012 0.9 Tunai
15 Feb 2012 02 Feb 2012 19 Mar 2012 1.95 Tunai
04 Aug 2011 28 Jul 2011 12 Sep 2011 0.85 Tunai
02 Feb 2011 27 Jan 2011 14 Mar 2011 1.85 Tunai
04 Aug 2010 29 Jul 2010 13 Sep 2010 0.7 Tunai
03 Feb 2010 28 Jan 2010 15 Mar 2010 1.71 Tunai
05 Aug 2009 30 Jul 2009 14 Sep 2009 0.59 Tunai
04 Feb 2009 29 Jan 2009 16 Mar 2009 1.5 Tunai
06 Aug 2008 31 Jul 2008 15 Sep 2008 0.55 Tunai
07 Feb 2008 04 Feb 2008 17 Mar 2008 1.35 Tunai
08 Aug 2007 27 Jul 2007 17 Sep 2007 0.52 Tunai
07 Feb 2007 01 Feb 2007 19 Mar 2007 1.23 Tunai
09 Aug 2006 27 Jul 2006 18 Sep 2006 0.49 Tunai
08 Feb 2006 02 Feb 2006 20 Mar 2006 0.92 Tunai
10 Aug 2005 29 Jul 2005 19 Sep 2005 0.38 Tunai
09 Feb 2005 27 Jan 2005 21 Mar 2005 0.645 Tunai
11 Aug 2004 22 Jul 2004 20 Sep 2004 0.295 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.05 1 1.53
2024 1.49 2 2.27
2023 1.45 2 2.15
2022 1.45 2 2.14
2021 1.40 2 2.40
2020 1.40 2 2.80
2019 1.40 2 2.81
2018 1.40 2 3.69
2017 1.40 2 4.04
2016 1.40 2 5.12
2015 2.35 2 6.92
2014 2.80 2 7.96
2013 2.80 2 9.43
2012 2.85 2 12.06
2011 2.70 2 11.67
2010 2.41 2 10.44
2009 2.09 2 8.91
2008 1.90 2 9.26
2007 1.75 2 8.17
2006 1.41 2 5.27
2005 1.03 2 4.22
2004 0.295 1 1.62
Papar semua
76.4376.4373.5273.5270.6170.6167.7067.7064.8064.80Mar 26Mar 26Mar 27Mar 27Mar 28Mar 28Mar 31Mar 31Apr 1Apr 1Apr 2Apr 2Apr 3Apr 3Apr 4Apr 4

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
1.0001.0000.5000.5000.0000.000-0.500-0.500-1.000-1.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda